Werewolf Therapeutics (HOWL) Cash from Operations (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Cash from Operations of 6629000.0 for Q2 2026, up 143.72% year-over-year from 2719976.08 in Q2 2025, and up 162.56% on a QoQ basis from 10597000.0 in Q1 2026.
Werewolf Therapeutics (HOWL) Cash from Operations (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Cash from Operations for 7 years, with the latest figure at 6629000.0 in Q2 2026.
- Cash from Operations for Q2 2026 came in at 6629000.0, up 143.72% year-over-year; the trailing twelve-month figure through Jun 2026 was 30148000.0 (up 50.44% YoY), and the FY2025 annual result was 60292000.0, down 7.3% from the prior year.
- Cash from Operations climbed to 6629000.0 in Q2 2026, from 10597000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 6629000.0 in Q2 2026 and troughed at 18948000.0 in Q1 2025.
- A 5-year average of 10758666.67 and a median of 12166000.0 in 2022 frame the typical range for Cash from Operations.
- The widest annual swing landed in 2023, when Cash from Operations tumbled 3504.29%; it then jumped 143.72% in 2026.
- A 5-year view of Cash from Operations shows it stood at 11870000.0 in 2022, then soared by 61.37% to 4585000.0 in 2023, then sank by 210.84% to 14252000.0 in 2024, then climbed by 22.65% to 11024000.0 in 2025, then jumped by 160.13% to 6629000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were 6629000.0 in Q2 2026, 10597000.0 in Q1 2026, and 11024000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Werewolf Therapeutics | 43.94 Mn | 43.94 Mn | - | 6.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.63 Mn |
| Jun 30, 2026 | 6.63 Mn |
| Mar 31, 2026 | -10.60 Mn |
| Mar 31, 2026 | -10.60 Mn |
| Dec 31, 2025 | -11.02 Mn |
| Dec 31, 2025 | -11.02 Mn |
| Sep 30, 2025 | -15.16 Mn |
| Sep 30, 2025 | -15.16 Mn |
| Jun 30, 2025 | -15.16 Mn |
| Jun 30, 2025 | -15.16 Mn |
| Mar 31, 2025 | -18.95 Mn |
| Mar 31, 2025 | -18.95 Mn |
| Dec 31, 2024 | -14.25 Mn |
| Dec 31, 2024 | -14.25 Mn |
| Sep 30, 2024 | -12.46 Mn |
| Sep 30, 2024 | -12.46 Mn |
| Jun 30, 2024 | -14.18 Mn |
| Jun 30, 2024 | -14.18 Mn |
| Mar 31, 2024 | -15.30 Mn |
| Mar 31, 2024 | -15.30 Mn |